A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 39
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CEL
Long Form : contrast enhancing lesions
No. Year Title Co-occurring Abbreviation
2020 Relationships between recurrence patterns and subventricular zone involvement or CD133 expression in glioblastoma. CTX, GBM, SVZ
2020 The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary? DMT, Gd
2019 Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis. CL, CL-V, DIR, MRI, MS, RRMS, WML
2019 Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. CW, FR, IFNB, RRMS
2019 Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. NEL
2019 Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma. MRI, nVS, rCBF
2019 The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. EDSS, MS
2018 A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). RRMS, SFE
2018 Apparent transverse relaxation (R2∗) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma. MRI, NEL, psPD
10  2018 Does proximity to the subventricular zone and expression of CXCR-4 and nestin affect prognosis in high-grade glioma? HGG, PFS, SVZ
11  2017 A generalized parametric response mapping method for analysis of multi-parametric imaging: A feasibility study with application to glioblastoma. ADC, LOOCV, MPRMs, OS, PRM, rCBV, RT
12  2017 Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. ADC, CNI, FA, MRI, NAV, NEL, rCBV
13  2017 T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis. MS, T1-DB, T1-SUB
14  2016 Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study. CIS, EDSS, MRI, MS, PBMCs, RRMS
15  2016 Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging. BH, CST, Gd, HC, MRI, MS, MWF, MWI, NAWM, ROI, WM
16  2016 High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study. DSC, MRA
17  2016 Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis. MRI, MS
18  2015 Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. ADC, OS, PFS, RT, T2L
19  2015 Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials. MS
20  2015 Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials. MR-pax, MS
21  2015 Survival prediction in high-grade gliomas using CT perfusion imaging. BF, BV, CT, MR, NEL, OS
22  2013 Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. anti-CMV, CIS, EA-D, EBV, VCA
23  2013 Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. MRI, MS
24  2013 The volumetric relationship of white matter lesion and contrast-enhanced lesion in delayed radiation brain injury: an MRI-based study. RBI, WML
25  2011 Intrathecal effects of daclizumab treatment of multiple sclerosis. MS, RRMS
26  2011 One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. BPF, MS, sMRI, T2LV
27  2008 Perivascular spaces--MRI marker of inflammatory activity in the brain? BBB, BPF, VRS
28  2008 Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. BH, MS, NB, PBH
29  2008 Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. MS, RR
30  2008 Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. GBM, LV
31  2007 Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. IFN, MS
32  2007 Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. DSC, GBM, MET
33  2007 Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. GBM, SVZ
34  2006 Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. BFV, IFN, PBVC, RRMS
35  2005 Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis. BH, IFN, MS
36  2004 Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. BV, CA, EDSS, IFNbeta-1b, NAb, RRMS, WMLL
37  2002 A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. MRI, MRS, MS, MTR, rhIGF-1, WMLL
38  2001 Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. IFN-CEL, IFNbeta-1b, IVMP, MTR, NAWM, ROIs, RRMS, S-CEL
39  2000 MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. BWMLL, RRMS